Actively Recruiting

Phase 3
Age: 65Years +
All Genders
ID04442412

Prephase Treatment With Prednisone With or Without Vitamin D Supplementation Followed by Immunochemotherapy in Elderly Patients With Diffuse Large B-Cell Lymphoma

Led by Fondazione Italiana Linfomi - ETS · Updated on 2022-08-26

430

Participants Needed

49

Research Sites

260 weeks

Total Duration

On this page

Sponsors

F

Fondazione Italiana Linfomi - ETS

Lead Sponsor

G

GRADE Onlus

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to evaluate the effects of adding Vitamin D supplementation to standard immunochemotherapy in elderly patients diagnosed with Diffuse Large B-Cell Lymphoma or Follicular grade IIIb lymphoma. This open-label, randomized phase III trial compares two treatment approaches to understand whether Vitamin D affects outcomes in patients aged 65 and older undergoing immunochemotherapy. Participants are randomly assigned to one of two groups. Both groups receive a prephase of oral prednisone followed by six cycles of immunochemotherapy with R-CHOP or R-miniCHOP every 21 days. The experimental group also receives Vitamin D supplementation starting before treatment and continuing through immunochemotherapy according to a set schedule, including loading doses based on baseline Vitamin D levels and weekly maintenance. Patients may continue Vitamin D supplementation after treatment for up to two years. During the study, participants undergo baseline assessments and are monitored regularly through the treatment cycles. Researchers track progression-free survival over 54 months as the primary outcome, along with overall survival, response rates, Vitamin D levels, physical functioning, and fatigue. Safety and treatment adherence are also monitored, with follow-up visits extending up to several years to evaluate long-term outcomes.

CONDITIONS

Brief Title

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Who Can Participate

Age: 65Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma or Follicular grade IIIb lymphoma per WHO 2017 classification
  • Age 65 years or older
  • Comprehensive Geriatric Assessment performed before treatment
  • Eastern Cooperative Oncology Group performance status 3 or less
  • Eligible for anthracycline-containing regimen (R-CHOP or R-miniCHOP)
  • No prior treatment for these lymphomas
  • Ann Arbor stage I to IV
  • At least one measurable nodal disease site (≥1.5 cm) or metabolically active site by FDG-PET
  • Serum Vitamin D levels 40 ng/mL or lower
  • Adequate blood counts: neutrophils >1.5 x 10^9/L unless marrow involvement; platelets ≥80,000/mm3 unless marrow involvement
  • Adequate kidney function: creatinine ≤2 mg/dL unless due to lymphoma
  • Adequate liver function: bilirubin ≤2 mg/dL unless due to lymphoma
  • Left ventricular ejection fraction >50%
  • Life expectancy of at least 6 months
  • Ability to understand and sign informed consent
  • Ability to comply with study visits and procedures
  • Men agree to use contraception during and for 3 months after treatment and not to donate sperm during the study
Not Eligible

You will not qualify if you...

  • Diagnosis other than Diffuse Large B-Cell Lymphoma or Follicular grade IIIb lymphoma, including high-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements
  • Vitamin D supplementation above 10,000 U/week as standard care
  • Suspected or confirmed central nervous system involvement by lymphoma
  • Contraindication to rituximab use
  • Contraindication to Vitamin D supplementation (such as hypercalcemia or hyperphosphatemia)
  • Received anti-cancer therapy within 14 days before study drug
  • Significant neurological, psychiatric, endocrine, metabolic, immunologic, or liver disease impairing consent or participation
  • History of other active cancers within 2 years except certain treated localized cancers
  • Clinically significant uncontrolled conditions, including active infections or hepatitis B/C requiring treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for baseline assessments and randomization

Prephase Treatment

Duration - 7 to 14 days

Participants receive a prephase treatment with oral prednisone, with or without Vitamin D supplementation depending on their assigned arm.

1 prephase visit (in-person)

Treatment

Duration - Approximately 18 weeks

Participants undergo 6 courses of immunochemotherapy with R-CHOP or R-miniCHOP every 21 days. Vitamin D supplementation continues for participants in the experimental arm according to their baseline Vitamin D levels.

6 treatment visits every 21 days

Follow-up

Duration - Up to 2 years

Participants may continue Vitamin D supplementation at a reduced dose monthly for up to 2 years and are followed for survival and treatment outcomes.

Monthly follow-up visits for Vitamin D supplementation and survival monitoring

Trial Site Locations

Total: 49 locations

1

SC Ematologia Spedali Civili

Brescia, BS, Italy

Actively Recruiting

2

UO Ematologia e CTMO di Piacenza

Piacenza, PC, Italy, 29121

Actively Recruiting

3

Ospedale Oncologico regionale CROB

Rionero in Vulture, Piacenza, Italy

Not Yet Recruiting

4

A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia

Alessandria, Italy, 15121

Actively Recruiting

5

A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona

Ancona, Italy, 60126

Actively Recruiting

6

Ascoli Piceno - Ospedale C.e G. Mazzoni - U.O.C. di Ematologia

Ascoli Piceno, Italy, 15121

Not Yet Recruiting

7

Aviano - Centro Riferimento Oncologico - S.O.C. Oncologia Medica A

Aviano, Italy

Actively Recruiting

8

Barletta - Ospedale "Monsignor Raffaele Dimiccoli" - Ematologia

Barletta, Italy

Not Yet Recruiting

9

Bergamo - Cliniche Humanitas Gavazzeni - Oncologia - Cliniche Humanitas Gavazzeni

Bergamo, Italy

Not Yet Recruiting

10

Biella - Ospedale Degli Infermi - S.C. Oncologia

Biella, Italy

Not Yet Recruiting

11

Campobasso - Universitа Cattolica del Sacro Cuore - Ematologia

Campobasso, Italy

Not Yet Recruiting

12

Castelfranco Veneto - Ospedale di Castelfranco Veneto - Ematologia

Castelfranco Veneto, Italy

Not Yet Recruiting

13

Unità Funzionale di Ematologia AOU Careggi

Florence, Italy

Actively Recruiting

14

Frosinone - Presidio Ospedaliero F. Spaziani - UOC Ematologia

Frosinone, Italy

Not Yet Recruiting

15

Matera - Ospedale Madonna delle Grazie - Ematologia

Matera, Italy

Not Yet Recruiting

16

Meldola - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia

Meldola, Italy

Actively Recruiting

17

Mestre - Ospedale Dell Angelo - U.O. Ematologia

Mestre, Italy

Not Yet Recruiting

18

SC Ematologia AO Niguarda Cà Granda

Milan, Italy, 20162

Not Yet Recruiting

19

Monza - ASST MONZA Ospedale S. Gerardo - Ematologia

Monza, Italy

Actively Recruiting

20

Napoli - AOU Universitа degli Studi della Campania Luigi Vanvitelli - Oncologia Medica ed Ematologia

Naples, Italy

Not Yet Recruiting

21

Università del Piemonte Orientale - Novara

Novara, Italy, 28100

Not Yet Recruiting

22

Padova - I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1

Padova, Italy

Not Yet Recruiting

23

Pagani - Presidio ospedaliero "A. TORTORA" - U.O. Onco-ematologia

Pagani, Italy

Not Yet Recruiting

24

Palermo - A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia

Palermo, Italy

Not Yet Recruiting

25

Palermo - AOU Policlinico Giaccone - Ematologia

Palermo, Italy

Actively Recruiting

26

UO Ematologia Università - Policlinico San Matteo

Pavia, Italy

Actively Recruiting

27

Pescara - P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi

Pescara, Italy

Not Yet Recruiting

28

Potenza - AOR San Carlo

Potenza, Italy

Not Yet Recruiting

29

UO Ematologia Ospedale Santa Maria delle Croci

Ravenna, Italy

Actively Recruiting

30

Reggio Emilia - AO Santa Maria Nuova

Reggio Emilia, Italy, 42123

Actively Recruiting

31

UO Ematologia - Ospedale degli Infermi

Rimini, Italy

Not Yet Recruiting

32

Roma - IRCCS Spallanzani - Servizio di Ematologia in malattie infettive

Roma, Italy

Not Yet Recruiting

33

Roma - Ospedale S. Camillo - Ematologia

Roma, Italy

Not Yet Recruiting

34

Roma - Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare

Roma, Italy

Actively Recruiting

35

Università Cattolica S. Cuore, Ematologia

Roma, Italy

Not Yet Recruiting

36

Università La Sapienza Ematologia

Roma, Italy

Not Yet Recruiting

37

UOC Ematologia - A.O. Sant'Andrea

Roma, Italy

Not Yet Recruiting

38

Salerno - Ematologia e Trapianti A.O. San Giovanni di Dio e Ruggi D Aragona - U.O. Ematologia

Salerno, Italy

Actively Recruiting

39

San Giovanni Rotondo - Casa Sollievo della Sofferenza - U.O. Ematologia

San Giovanni Rotondo, Italy

Not Yet Recruiting

40

Sassari - AOU di Sassari - Ematologia

Sassari, Italy

Not Yet Recruiting

41

UOC Medicina Interna MO DH Oncologico

Sassuolo, Italy

Actively Recruiting

42

UOC Ematologia, AOU Senese

Siena, Italy

Actively Recruiting

43

Univ. Perugia Sede Terni - Oncoematologia

Terni, Italy

Actively Recruiting

44

AOU Citta della Salute e della Scienza di Torino - Ematologia Universitaria

Torino, Italy, 10126

Actively Recruiting

45

SC. Ematologia A.O. Città della Salute e della Scienza

Torino, Italy

Actively Recruiting

46

Torino - San Giovanni Bosco - ASL Cittа di Torino - SSD di Ematologia e Malattie Trombotiche

Torino, Italy

Not Yet Recruiting

47

Trieste - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia

Trieste, Italy, 34121

Actively Recruiting

48

Udine - Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - SOC Clinica Ematologica

Udine, Italy

Not Yet Recruiting

49

ULSS 8 Berica - Ospedale S. Bortolo - Ematologia

Vicenza, Italy

Actively Recruiting

Loading map...

Research Team

L

Lorenza Randi, Dott.ssa

F

Francesco Merli, Dott.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) L...

Chronic Lymphocytic Leukemia

Actively Recruiting

175 locations

A Phase 3, Open-label, Randomized Study of SHR-A1912 Combine...

Diffuse Large B-cell Lymphoma

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here